Background: Low bone mineral density caused by the skeletal related illness. osteoporosis increases the risk of bone fractures and makes a person more fragile. The hip, spine, shoulder, and wrist are the bones most commonly afflicted. The most common reason is a decrease in bone mineral density, with hip and spinal fractures and other skeletal being the most hazardous. While osteoporosis is frequent in elderly age, after menopause women are more susceptible. It reduces mobility by causing stooped posture, height loss, and persistent discomfort. Because nanotechnology can manipulate molecules and supramolecular structures, it has the potential to completely change how drugs are delivered. Ibandronate is one of the nanoparticles that can be employed in biotechnology and medicine to treat osteoporosis. On the other hand, the primary obstacles consist of limited bioavailability and adverse consequences such as gastric ulcers. Method: The preparation of the polymeric nanoparticle formulations involved modifying the nanoprecipitation technique. In short, a certain volume of Eudragit RL100, 1,4 dioxane solutions were prepared, and water was used to dissolve AS and Polyvenyl Alcohol. Then, to start the nanoprecipitation process, the polymeric solution was added to the aqueous solution while being stirred. When the 1,4 dioxane are evaporated completely, the stirring procedure was maintained continuous. Ultimately, the result material underwent centrifugation. Three rounds of double-distilled water are used for washing, and freeze-dried to produce powdered nanoparticles. The evaluation of nanoparticles included % yield, Zeta potential, particle size, FTIR, PDI, and SEM. Result: Ibandronate loaded polymeric Nanoparticles of Eudragit RL100 are produced in this study using mannitol, organic solvent, polyvinyl alcohol as surfactant and Eudragit RL100 as polymer. Based on testing report the ideal formulation was identified. An increase in PVA concentration was shown to cause the greatest change in particle size, improving the drug interaction and cross linking density of the polymer. A maximum drug entrapment of 76.3% and an average particle size of 226.57 nm were observed in the improved formulation. Conclusion: The study focuses on the preparation of polymeric nanoparticle formulations using modified nanoprecipitation techniques. Eudragit RL100 (polymer), 1,4 dioxane (Organic solvent), polyvinyl alcohol (surfactant) and Mannitol as cryoprotectant are used. The nanoparticles were evaluated for yield, zeta potential, particle size, FTIR, PDI and SEM. The ideal formulation was identified, with a maximum drug entrapment of 76.3% and a smaller particle size of 226.57 nm and many other reported data.